Linked Life Data

18755287

Source:http://linkedlifedata.com/resource/pubmed/id/18755287

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
21-22
pubmed:dateCreated
2008-10-28
pubmed:abstractText
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. There is a substantial need for new chemotherapeutic drugs effective against this tumor. Doxorubicin (DOXO), used for chemoembolization of HCCs, is poorly efficacious when administered systemically at conventional doses; dose escalation is hindered by unacceptable toxicity. Here, we review preclinical experiments showing that the efficacy of DOXO against HCCs and its safety increased following conjugation to lactosaminated human albumin (L-HSA). L-HSA-DOXO was initially prepared to improve the anticancer activity of the drug on well-differentiated HCCs, which actively internalize L-HSA by means of the asialoglycoprotein receptor. Unexpectedly, it was found that the conjugate enhanced DOXO concentrations in all forms of HCCs, independently of their differentiation grade.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1359-6446
pubmed:author
pubmed:issnType
Print
pubmed:volume
13
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1002-9
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Doxorubicin coupled to lactosaminated human albumin: a hepatocellular carcinoma targeted drug.
pubmed:affiliation
Department of Experimental Pathology, University of Bologna, Italy. luigi.fiume@unibo.it
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't